International Psoriasis Council
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: IFN-k is a rheostat for development of psoriasiform inflammation
University of Modena & Reggio Emiliana
Modena, Italy
PUBLICATION
IFN-k is a rheostat for development of psoriasiform inflammation. Gharaee-Kermani M, Estadt SN, Tsoi LC, Wolf-Fortune SJ, Liu J, Xing X, Theros J, Reed TJ, Lowe L, Gruszka D, Ward NL, Gudjonsson JE, Kahlenberg JM. J Invest Dermatol. 2022 Jan;142(1):155-165.e3. doi: 10.1016/j.jid.2021.05.029. Epub 2021 Aug 5. PMID: 34364883; PMCID: PMC8688309.
Why this article was chosen
Commentary
As pointed out by Garzorz-Stark and Kilian Eyerich1 in the Commentary related to the present article, in psoriatic skin, there are two immune axes involving IFNs: pDC-derived IFN-a and keratinocytes-derived IFN-k, both leading to type 1 (Th1, IL-12, and IFN-g) and type 3 (IL-23, Th17, IL-17) immune responses. This also implies an active role for keratinocytes in psoriasis.
Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)
Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older
Un Enfoque en Psoriasis: Un Reporte de el Congreso RADLA 2022
Also Read
Commentary: Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis
Sleep disorders are frequently found in patients with psoriasis, but the specific factors have remained elusive and have never been studied comprehensively. Esteban Dauden-Tello shares his expert opinion on a study which outlines the prevalence and characteristics associated with this still enigmatic aspect of psoriasis.
Commentary: Biomarkers of Disease Progression in Psoriasis: Current State-of-the-Art
In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their clinical significance for psoriasis progression. Read commentary from Andrea Chiricozzi, MD, on three recent publications.
Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic
The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat.
Subscribe to the IPC Newsletter